|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shao C, Guo H, Chen L, Chen J, Wang L and
Wang H: Prognostic factors and clinic-pathologic characteristics of
ovarian tumor with different histologic subtypes-a SEER database
population study of 41,376 cases. Transl Cancer Res. 12:1937–1950.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lavoro A, Scalisi A, Candido S, Zanghì GN,
Rizzo R, Gattuso G, Caruso G, Libra M and Falzone L: Identification
of the most common BRCA alterations through analysis of germline
mutation databases: Is droplet digital PCR an additional strategy
for the assessment of such alterations in breast and ovarian cancer
families? Int J Oncol. 60:582022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sekine M, Nishino K and Enomoto T:
Differences in ovarian and other cancers risks by population and
BRCA mutation location. Genes (Basel). 12:10502021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vos S, van Diest PJ and Moelans CB: A
systematic review on the frequency of BRCA promoter methylation in
breast and ovarian carcinomas of BRCA germline mutation carriers:
Mutually exclusive, or not? Crit Rev Oncol Hematol. 127:29–41.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kurman RJ and Shih IM: The dualistic model
of ovarian carcinogenesis: Revisited, revised, and expanded. Am J
Pathol. 186:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Doubeni CA, Doubeni AR and Myers AE:
Diagnosis and management of ovarian cancer. Am Fam Physician.
93:937–944. 2016.PubMed/NCBI
|
|
10
|
Chandra A, Pius C, Nabeel M, Nair M,
Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status
and strategies for improving therapeutic outcomes. Cancer Med.
8:7018–7031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cortez AJ, Tudrej P, Kujawa KA and
Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother
Pharmacol. 81:17–38. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alshamrani AA: Roles of microRNAs in
ovarian cancer tumorigenesis: Two decades later, what have we
learned? Front Oncol. 10:10842020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee RC, Feinbaum RL and Ambrost V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kinose Y, Sawada K, Nakamura K and Kimura
T: The role of microRNAs in ovarian cancer. Biomed Res Int.
2014:2493932014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC and Mulrow CD: PRISMA_2020_flow_diagram_new_SRs_v1
[Internet]. BMJ. 3722017.Available from:. http://www.prisma-statement.org/PRISMAStatement/FlowDiagram
|
|
16
|
Aldossary SA: Review on pharmacology of
cisplatin: Clinical use, toxicity and mechanism of resistance of
cisplatin. Biomed Pharmacol J. 12:7–15. 2019. View Article : Google Scholar
|
|
17
|
Stelzer G, Rosen N, Plaschkes I, Zimmerman
S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, et
al: The GeneCards suite: From gene data mining to disease genome
sequence analyses. Curr Protoc Bioinformatics. 54:1.30.1–1.30.33.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang S, Li MY, Liu Y, Vlantis AC, Chan
JYK, Xue L, Hu BG, Yang S, Chen MX, Zhou S, et al: The role of
microRNA in cisplatin resistance or sensitivity. Expert Opin Ther
Targets. 24:885–897. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Zeng G and Jiang Y: The emerging
Roles of miR-125b in cancers. Cancer Manag Res. 12:1079–1088. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan JK, Blansit K, Kiet T, Sherman A,
Wong G, Earle C and Bourguignon LY: The inhibition of miR-21
promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol
Oncol. 132:739–744. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Jiang K and Zhao F: Icariin
regulates the proliferation and apoptosis of human ovarian cancer
cells through microRNA-21 by targeting PTEN, RECK and Bcl-2. Oncol
Rep. 33:2829–2836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang XY, Li YF, Ma H and Gao YH:
Regulation of MYB mediated cisplatin resistance of ovarian cancer
cells involves miR-21-wnt signaling axis. Sci Rep. 10:68932020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gong J, Xing C, Wang LY, Xie SS and Xiong
WD: L-Tetrahydropalmatine enhances the sensitivity of human ovarian
cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade. J BUON.
24:701–708. 2019.PubMed/NCBI
|
|
24
|
Chen Y, Wang L and Zhou J: Effects of
microRNA-1271 on ovarian cancer via inhibition of
epithelial-mesenchymal transition and cisplatin resistance. J
Obstet Gynaecol Res. 45:2243–2254. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ge T, Liu T, Guo L, Chen Z and Lou G:
MicroRNA-302 represses epithelial-mesenchymal transition and
cisplatin resistance by regulating ATAD2 in ovarian carcinoma. Exp
Cell Res. 396:1122412020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Ai H, Fan X, Chen S, Wang Y and
Liu L: Knockdown of long non-coding RNA HOTAIR reverses cisplatin
resistance of ovarian cancer cells through inhibiting
miR-138-5p-regulated EZH2 and SIRT1. Biol Res. 53:182020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J and Liu L: MiR-149-3p promotes the
cisplatin resistance and EMT in ovarian cancer through
downregulating TIMP2 and CDKN1A. J Ovarian Res. 14:1652021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin AH and Wei ZL: Molecular mechanism of
increased sensitivity of cisplatin to ovarian cancer by inhibition
of microRNA-23a expression. Int J Clin Exp Med. 8:13329–13334.
2015.PubMed/NCBI
|
|
29
|
Chhabra R, Dubey R and Saini N:
Cooperative and individualistic functions of the microRNAs in the
miR-23a~27a~24-2 cluster and its implication in human diseases. Mol
Cancer. 9:2322010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
García-Vázquez R, Gallardo Rincón D,
Ruiz-García E, Meneses García A, Hernández De La Cruz ON,
Astudillo-De La Vega H, Isla-Ortiz D, Marchat LA, Salinas-Vera YM,
Carlos-Reyes Á, et al: let-7d-3p is associated with apoptosis and
response to neoadjuvant chemotherapy in ovarian cancer. Oncol Rep.
39:3086–3094. 2018.PubMed/NCBI
|
|
31
|
Zheng H, Zhang L, Zhao Y, Yang D, Song F,
Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as diagnostic
and prognostic biomarkers for ovarian cancer. PLoS One.
8:e778532013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Langhe R, Norris L, Saadeh FA,
Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin
C, O'Donnell DM, et al: A novel serum microRNA panel to
discriminate benign from malignant ovarian disease. Cancer Lett.
356:628–636. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kobayashi M, Salomon C, Tapia J, Illanes
SE, Mitchell MD and Rice GE: Ovarian cancer cell invasiveness is
associated with discordant exosomal sequestration of Let-7 miRNA
and miR-200. J Transl Med. 12:42014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chung YW, Bae HS, Song JY, Lee JK, Lee NW,
Kim T and Lee KW: Detection of microRNA as novel biomarkers of
epithelial ovarian cancer from the serum of ovarian cancer
patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumor Biol. 37:10499–10506. 2016. View Article : Google Scholar
|
|
36
|
Bieg D, Sypniewski D, Nowak E and Bednarek
I: MiR-424-3p suppresses galectin-3 expression and sensitizes
ovarian cancer cells to cisplatin. Arch Gynecol Obstet.
299:1077–1087. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun KX, Jiao JW, Chen S, Liu BL and Zhao
Y: MicroRNA-186 induces sensitivity of ovarian cancer cells to
paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res.
8:802015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bertucci A, Kim KH, Kang J, Zuidema JM,
Lee SH, Kwon EJ, Kim D, Howell SB, Ricci F, Ruoslahti E, et al:
Tumor-targeting, MicroRNA-silencing porous silicon nanoparticles
for ovarian cancer therapy. ACS Appl Mater Interfaces.
11:23926–23937. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Javanmardi S, Tamaddon AM, Aghamaali MR,
Ghahramani L and Abolmaali SS: Redox-sensitive, PEG-shielded
carboxymethyl PEI nanogels silencing MicroRNA-21, sensitizes
resistant ovarian cancer cells to cisplatin. Asian J Pharm Sci.
15:69–82. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vandghanooni S, Eskandani M, Barar J and
Omidi Y: Antisense LNA-loaded nanoparticles of star-shaped
glucose-core PCL-PEG copolymer for enhanced inhibition of
oncomiR-214 and nucleolin-mediated therapy of cisplatin-resistant
ovarian cancer cells. Int J Pharm. 573:1187292020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gandham SK, Rao M, Shah A, Trivedi MS and
Amiji MM: Combination microRNA-based cellular reprogramming with
paclitaxel enhances therapeutic efficacy in a relapsed and
multidrug-resistant model of epithelial ovarian cancer. Mol Ther
Oncolytics. 25:57–68. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao Z, Shuang T, Gao Y, Lu F, Zhang J, He
W, Qu L, Chen B and Hao Q: Targeted delivery of exosomal miR-484
reprograms tumor vasculature for chemotherapy sensitization. Cancer
Lett. 530:45–58. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rupaimoole R, Ivan C, Yang D, Gharpure KM,
Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M,
et al: Hypoxia-upregulated microRNA-630 targets Dicer, leading to
increased tumor progression. Oncogene. 35:4312–4320. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ye G, Fu G, Cui S, Zhao S, Bernaudo S, Bai
Y, Ding Y, Zhang Y, Yang BB and Peng C: MicroRNA 376c enhances
ovarian cancer cell survival by targeting activin receptor-like
kinase 7: Implications for chemoresistance. J Cell Sci.
124:359–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Echevarría-Vargas IM, Valiyeva F and
Vivas-Mejía PE: Upregulation of miR-21 in cisplatin resistant
ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 9:e970942014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vandghanooni S, Eskandani M, Barar J and
Omidi Y: AS1411 aptamer-decorated cisplatin-loaded
poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of
miR-21-inhibited ovarian cancer cells. Nanomedicine (Lond).
13:2729–2758. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Suardi RB, Ysrafil Y, Sesotyosari SL,
Martien R, Wardana T, Astuti I and Haryana SM: The effects of
combination of mimic miR-155-5p and antagonist miR-324-5p
encapsulated chitosan in ovarian cancer SKOV3. Asian Pac J Cancer
Prev. 21:2603–2608. 2020. View Article : Google Scholar : PubMed/NCBI
|
